Just askin’.

It’s clear that opioid use disorder has gotten more prevalent since the pandemic began, both nationally and in Vermont. The Centers for Disease Control published a report in December that said overdose deaths rose sharply after the onset of the Covid-19 pandemic, due to “a larger supply of illegal drugs, reduced access to addiction and overdose treatment, and the lethality of synthetic fentanyl.” A study published in Population Health Management reports that, while testing for illicit drugs plummeted in the early weeks of the pandemic, positive test results for opioids went through the roof.

The American Medical Association says that “More than 40 states have reported increases in opioid-related mortality as well as ongoing concerns for those with a mental illness or substance use disorder,” and recommended action “to remove barriers to evidence-based treatment for those with a substance use disorder as well as for harm reduction services.”

Which leads me to the question posed above.

Maybe there has been an expansion of treatment, harm reduction and availability of naloxone, buprenorphine and other relevant medications. Maybe the feds’ Covid relief bills brought some funding to the states for such programs. Maybe the state acted on its own to fight this aspect of the pandemic’s impact on society.

But if they have, it’s news to me.

Continue reading →